ADJUVANT THERAPY OF AUTOIMMUNE HEPATITIS
Abstract
Aim of study. To examine the possibility of adjuvant therapy in the treatment of autoimmune hepatitis. The theoretical background and the existing research on the use of hepatotropic drugs in autoimmune hepatitis have been considered. We discuss the situation when the therapy of autoimmune hepatitis can be supplemented by non-conventional medicines. It must be assumed that the treatment of autoimmune hepatitis should not always be limited to immunosuppression schemes, and in some cases may be enhanced by drugs that provide additional effects. The most promising agents for adjuvant therapy of autoimmune hepatitis are ursodeoxycholic and glycyrrhiziс acids.
About the Authors
K. L. Raikhelson
Federal state budget institution of higher education “North-Western State Medical University named after I. I. Mechnikov” under the Ministry of Public Health of the Russian Federation
Russian Federation
Russian Federation
S. N. Mehtiev
State budget institution of higher professional education “Pavlov First Saint Petersburg State Medical University“ under the Ministry of Public Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Soloway, R. D. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis / R. D. Soloway, W. Summerskill H., A. H. Baggenstoss [et al.] // Gastroenterol. - 1972. - Vol. 63., № 5. - P. 820-833.
2. Gleeson, D. British Society of Gastroenterol. (BSG) guidelines for management of autoimmune hepatitis / D. Gleeson, M. A. Heneghan, British Society of Gastroenterol. // Gut. - 2011. - Vol. 60, № 12. - P. 1611-1629.
3. EASL Clinical Practice Guidelines: Autoimmune hepatitis // J. Hepatol. - 2015. - Vol. 63. - P. 971-100.
4. Ивашкин В. Т., Буеверов А. О., Маевская М. В., Абдулганиева Д. И. Клинические рекомендации по диагностике и лечению аутоиммунного гепатита. / Российская Гастроэнтерологическая Ассоциация. Российское общество по изучению печени 2013. URL. http://www.gastro.ru/?pageId=41. (Последнее обращение 15.08.2015).
5. EASL Clinical Practice Guidelines: Autoimmune hepatitis // J. Hepatol. - 2015. - Vol. 63. - P. 971-1004.
6. Manns, M. P. Diagnosis and management of autoimmune hepatitis / M. P. Manns, A. J. Czaja, J. D. Gorham [et al.] American Association for the Study of Liver Diseases // Hepatol. - 2010. - Vol. 51, № 6. - P. 2193-2213.
7. Czaja, A. J. Autoimmune hepatitis: focusing on treatments other than steroids. // Can J Gastroenterol. - 2012. - Vol. 26, № 9. - P. 615-620.
8. Czaja, A. J. Hepatic inflammation and progressive hepatic fibrosis in chronic liver disease. // World J Gastroenterol. - 2014. - Vol. 20, № 10. - P. 2515-2532.
9. Czaja, A. J. Difficult treatment decisions in autoimmune hepatitis. /World J. Gastroenterol. - 2010. - V. 16, N.8. - P. 934-947.
10. EASL Clinical Practice Guidelines: Wilson’s disease. // J. Hepatol. - 2012. - Vol. 56, № 3. - P. 671-685
11. Castiella, A. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. // A. Castiella, E. Zapata, M. I. Lucena, R. J. Andrade - World J. Hepatol. - 2014. - Vol. 6. № 4. - P. 160-168.
12. Czaja, A. J. Drug-induced autoimmune-like hepatitis. // Dig. Dis. Sci. - 2011. - Vol. 56. - P. 958-976.
13. Czaja, A. J. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis./ A. J. Czaja, H. A Carpenter // J. Hepatol. - 2004. - Vol. 40, № 4. - P. 646-652.
14. Mohamadnejad, M. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. / M. Mohamadnejad, R. Malekzadeh, S. Nasseri-Moghaddam [et al.] // Dig Dis Sci. - 2005. - P. 50, № 3. - P. 547-551.
15. Райхельсон, К. Л. Опыт лечения аутоиммунного гепатита и его перекрестных синдромов с холестатическими заболеваниями // К. Л. Райхельсон, Н. В. Семенов, А. Ю. Барановский / Вестник Северо-Западного государственного медицинского университета им. И. И. Мечникова. 2013. - Т. 5, № 2. - С. 80-84.
16. Сzaja, A. J. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis./ A. J. Сzaja, K. V. Menon, H. A. Carpenter // Hepatol. - 2002. - Vol.35, № 4. - P. 890-897
17. Abe, M. Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan. Present status of autoimmune hepatitis in Japan: a nationwide survey. / M. Abe, T. Mashiba, M. Zeniya, K. Yamamoto [et al.] // J. Gastroenterol. - 2011. - Vol.46, № 9. - P. 1136-1141.
18. Kotb, M. A. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode./ M. A. Kotb // Int. J. Mol. Sci. - 2012. - Vol.13. № 7. - P. 8882-8914.
19. Amaral, J. D. Bile acids: regulation of apoptosis by ursodeoxycholic acid / J. D Amaral., Р. J. S. Viana, R. M. Ramalho [et al.] // J. Lipid. Res. - 2009 - Vol. 50, № 9. - P. 1721-1734.
20. Czaja A. J., Carpenter H. A., Lindor K. D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. / Hepatol. - 1999. - V. 30, N. 6. - P. 1381-1386.
21. Nakamura, K. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. / K. Nakmaura, M. Yoneda, S. Yokohama [et al.] // J. Gastroenterol. Hepatol. - 1998- Vol.13, N. 5., - P. 490-495.
22. Miyake Y., Iwasaki Y., Kobashi H. et al. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. // Hepatology Int. - 2009. - Vol.3, N. 4. - P. 556-562
23. Li, J. Y. Glycyrrhizic аcid in the treatment of liver diseases: literature review / J. Y. Li, H. Y. Cao, P. Liu [et al.] / Biomed Res Int. - 2014. - 872139. [Электронный ресурс] URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052927
24. Tang, B. Glycyrrhizin attenuates endotoxin- induced acute liver injury after partial hepatectomy in rats. / B. Tang, H. Qiao, F. Meng, X. Sun / Braz. J. Med. Biol. Res. // 2007. - Vol.40, № 12. - P. 1637-1646.
25. Abe, M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. / M. Abe, F. Akbar, A. Hasebe [et al.] // J. Gastroenterol. - 2003. - Vol.38, № 10. - P. 962-967.
26. Tu, C-T. Glycyrrhizin regulates CD4+T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway. / C. - T. Tu, J. Li, F. - P. Wang [et al.] // Int. Immunopharmacol. - 2012.- Vol.14, № 4. - P. 410-421.
27. Yasui, S. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis. / S. Yasui, K. Fujiwara, A. Tawada [et al.] // Dig. Dis. Sci. - 2011. - Vol.56, № 12. - P. 3638-3647.
28. Zhixiang С. Glycyrrhizin treatment on the efficacy of autoimmune hepatitis /. C. Zhixiang, H. Weiwen, S. F. Jue / Сlinical Medicine Papers. - 2011. [Электронный ресурс] URL. http://eng.hi138.com/medicine-papers/clinical-medicine-papers/201105/310244_glycyrrhizin-treatment-on-the-efficacy-of-autoimmune-hepatitis.asp#.Vd8NzCXtlHw.
29. Ramli, E. S. Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis. / Ramli E. S., Suhaimi F., Asri S. F. / Ramli E. S., Suhaimi F., Asri S. F. [et al.] // J. Bone Miner. Metab. - 2013. - Vol.31, № 3. - P. 262-273.
30. Sanz-Cameno, P. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. / Sanz- P. Cameno, J. Medina, L. García-Buey [et al.] // J. Hepatol. - 2002. - Vol.37, № 6. - P. 723-729.
Review
For citations:
Raikhelson K.L., Mehtiev S.N. ADJUVANT THERAPY OF AUTOIMMUNE HEPATITIS. Experimental and Clinical Gastroenterology. 2016;(4):80-85. (In Russ.)
Views:
1016
Email this article 